SCHEMBL24470896

SCHEMBL24470896

Cc1oc2ccc(OCc3c(F)cccc3F)cc2c1C(=O)NC1CCNC1=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ANO1 Q5XXA6 3/20 0.50
LMNA P02545 3/20 0.44
HTT P42858 1/20 0.44
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
TP53 P04637 1/20 0.43
MAPT P10636 3/20 0.43
TSHR P16473 2/20 0.43
SLC26A4 O43511 5/20 0.43
KMT2A Q03164 5/20 0.42
MEN1 O00255 4/20 0.42
APOL1 O14791 1/20 0.42
GAA P10253 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.41
ROCK1 Q13464 1/20 0.41
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24470910 0.91 SLC26A4 (0.47) ANO1LMNAHTTCASP3SENP8
SCHEMBL29713008 0.91 SLC26A4 (0.47) ANO1LMNAHTTCASP3SENP8
SCHEMBL29712951 0.91 SLC26A4 (0.51) LMNAHTTCASP3SENP8SENP7
SCHEMBL29712964 0.87 CASP3 (0.60) LMNAHTTCASP3SENP8SENP7
SCHEMBL24470575 0.87 CASP3 (0.60) LMNAHTTCASP3SENP8SENP7
SCHEMBL29713109 0.87 CASP3 (0.60) LMNAHTTCASP3SENP8SENP7
SCHEMBL24470772 0.87 CASP3 (0.60) LMNAHTTCASP3SENP8SENP7
SCHEMBL24470581 0.87 CASP3 (0.60) LMNAHTTCASP3SENP8SENP7
SCHEMBL24470663 0.85 KMT2A (0.49) ANO1LMNAHTTCASP3SENP8
SCHEMBL24485179 0.85 CASP3 (0.46) LMNAHTTCASP3SENP8SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391739-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2023-12-07 US claimed
EP-4259613-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2023-10-18 EP claimed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO claimed
US-20230391739-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2023-12-07 US disclosed
EP-4259613-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2023-10-18 EP disclosed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed
WO-2022112345-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391739-A1 ARYL DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPV3, TRPM6, TRPM4 ANO1 733/4885LMNA 3256/4885HTT 2395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.